BUSINESS
Eli Lilly blows past estimates, hikes sales outlook as Zepbound and Mounjaro demand surge again
CNBC BusinessThursday, October 29, 2026 at 11:44 AM
RedScroll Brief
Eli Lilly reported that sales of obesity drug Zepbound and diabetes treatment Mounjaro surged again in the third quarter.
RedScroll Signal
- Impact
- High
- Category
- Business
- Market relevance
- High
- Why it matters
- Corporate and market moves reprice risk and reveal where power and cash are concentrating. Eli Lilly reported that sales of obesity drug Zepbound and diabetes treatment Mounjaro surged again in the third quarter. Investors will watch earnings, rates, and competitive positioning connected to Eli Lilly and Zepbound.
Desk copy
RedScroll Briefing
Extractive editorial brief — not a reprint of the original
What happened
Eli Lilly reported that sales of obesity drug Zepbound and diabetes treatment Mounjaro surged again in the third quarter.
Why it matters
Corporate and market moves reprice risk and reveal where power and cash are concentrating.
Background
CNBC Business reported on this under business. RedScroll surfaces the signal with an extractive brief — not a reprint of the original article. Read the source for full reporting.
Timeline
CNBC Business published: Eli Lilly blows past estimates, hikes sales outlook as Zepbound and Mounjaro demand surge again
Story is in today’s RedScroll edition. Follow the original source for updates.
Economic impact
Investors will watch earnings, rates, and competitive positioning connected to Eli Lilly and Zepbound.
More on
Related stories
- Merck tops quarterly estimates, hikes profit outlook as new Keytruda form shows strength
CNBC BusinessBUSINESS
- Sprouts Slashes Outlook After Cyclospora Outbreak Hit Sales
Bloomberg MarketsBUSINESS
- Chipotle shares rise 7% after CEO says same-store sales growth will continue
CNBC BusinessBUSINESS
- FedEx beats expectations, raises outlook in first report since calendar adjustment
CNBC BusinessBUSINESS
- Weil’s collapse and the death of corporate loyalty
The Economist BusinessBUSINESS
- India’s ultra-cheap internet is about to get more expensive
The Economist BusinessBUSINESS
Source
CNBC Business
Original reporting by CNBC Business. RedScroll provides an extractive briefing only.